Sinopharm Group Co. Ltd. has circulated a proxy form for an Extraordinary General Meeting (EGM) to be held at 9:00 a.m. on 15 September 2026 in Meeting Room 1401, Sinopharm Group Building, No. 385 East Longhua Road, Huangpu District, Shanghai, China.

The agenda comprises 15 ordinary resolutions, all relating to the re-election of directors for the company’s seventh board session:

• Executive directors: Mr. Lian Wanyong and Mr. Yang Binghua. • Non-executive directors: Mr. Jin Bin, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Ma Yue, Mr. Chen Yuqing, Mr. Wen Deyong, and Ms. Li Ying. • Independent non-executive directors: Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng, Mr. Shi Shenghao, and Mr. Chen Weiru.

For each nominee, shareholders are asked to approve re-election, authorize the Board to determine remuneration, and permit the Board chairman or any executive director to execute service contracts or related agreements.

Voting arrangements:

1. Shareholders may appoint the Board chairman or another individual as proxy; multiple proxies are permitted but may vote only by poll. 2. Proxy forms, together with notarised powers of attorney if applicable, must be lodged no later than 24 hours before the meeting: – H-share holders: Computershare Hong Kong Investor Services Limited, 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong. – Domestic-share holders: Room 1413, Sinopharm Group Building, No. 385 East Longhua Road, Huangpu District, Shanghai 200023, China.

Only the first-named joint shareholder is entitled to vote. The company advises attendees to arrange their own travel and accommodation and to present valid identification at registration. The EGM is expected to conclude within half a day.

Sinopharm Group is incorporated in the People’s Republic of China as a joint-stock limited company and is registered in Hong Kong as a non-Hong Kong company under the English name “Sinopharm Group Co. Ltd.”